Prevalence and Prevention of Contact Dermatitis Caused by FreeStyle Libre: A Monocentric Experience

被引:41
作者
Pyl, Jeroen [1 ,2 ]
Dendooven, Ella [1 ,2 ]
Van Eekelen, Ine [1 ,2 ]
den Brinker, Marieke [2 ,3 ]
Dotremont, Hilde [2 ,3 ]
France, Annick [2 ,3 ]
Foubert, Kenn [2 ,4 ]
Pieters, Luc [2 ,4 ]
Lambert, Julien [1 ,2 ]
De Block, Christophe [2 ,5 ]
Aerts, Olivier [1 ,2 ]
机构
[1] Antwerp Univ Hosp, Dept Dermatol, Antwerp, Belgium
[2] Univ Antwerp, Antwerp, Belgium
[3] Antwerp Univ Hosp, Dept Pediat, Div Pediat Endocrinol, Antwerp, Belgium
[4] Univ Antwerp, Dept Pharmaceut Sci, Nat ral Prod & Food Res & Anal, Antwerp, Belgium
[5] Antwerp Univ Hosp, Dept Endocrinol Diabetol & Metab Dis, Antwerp, Belgium
关键词
RECOMMENDATIONS;
D O I
10.2337/dc19-1354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Cutaneous adverse events (CAE) from FreeStyle Libre include allergic contact dermatitis (ACD) caused by the allergen isobornyl acrylate (IBOA). We aim to report CAE from this glucose sensor, ACD to IBOA in particular, and the outcome of using barrier films as a prevention. RESEARCH DESIGN AND METHODS A monocentric, retrospective review of medical files from adult and pediatric patients with diabetes using Freestyle Libre, in the period between December 2016 and April 2019, was performed with a focus on CAE. RESULTS Fifty-seven of 1,036 patients with diabetes (5.5%) were referred to our dermatology department because of CAE from FreeStyle Libre. Thirty-nine of 1,036 (3.8%) had ACD due to IBOA. Only two patients, of whom one sensitized to IBOA, had a benefit from using barrier films. CONCLUSIONS CAE occurred in 5.5% of FreeStyle Libre users, and 3.8% suffered from ACD due to IBOA. Barrier films had limited value in the prevention.
引用
收藏
页码:918 / 920
页数:3
相关论文
共 15 条
[1]   FreeStyle Libre: contact irritation versus contact allergy [J].
Aerts, Olivier ;
Herman, Anne ;
Bruze, Magnus ;
Goossens, An ;
Mowitz, Martin .
LANCET, 2017, 390 (10103) :1644-1644
[2]  
[Anonymous], 2019, MISE DISPOSITION DIS
[3]   Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial [J].
Bolinder, Jan ;
Antuna, Ramiro ;
Geelhoed-Duijvestijn, Petronella ;
Kroeger, Jens ;
Weitgasser, Raimund .
LANCET, 2016, 388 (10057) :2254-2263
[4]   Clinical Practice Recommendations on the Routine Use of Eversense, the First Long-Term Implantable Continuous Glucose Monitoring System [J].
Deiss, Dorothee ;
Szadkowska, Agnieszka ;
Gordon, Debbie ;
Mallipedhi, Akhila ;
Schuetz-Fuhrmann, Ingrid ;
Aguilera, Eva ;
Ringsell, Corina ;
De Block, Christophe ;
Irace, Concetta .
DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (05) :254-264
[5]   Allergic contact dermatitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor [J].
Herman, Anne ;
Aerts, Olivier ;
Baeck, Marie ;
Bruze, Magnus ;
De Block, Christophe ;
Goossens, An ;
Hamnerius, Nils ;
Huygens, Sara ;
Maiter, Dominique ;
Tennstedt, Dominique ;
Vandeleene, Bernard ;
Mowitz, Martin .
CONTACT DERMATITIS, 2017, 77 (06) :367-373
[6]   Allergic contact dermatitis caused by glucose sensors in type 1 diabetes patients [J].
Hyry, Heli S. I. ;
Liippo, Jussi P. ;
Virtanen, Hannele M. .
CONTACT DERMATITIS, 2019, 81 (03) :161-166
[7]   European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice [J].
Johansen, Jeanne D. ;
Aalto-Korte, Kristiina ;
Agner, Tove ;
Andersen, Klaus E. ;
Bircher, Andreas ;
Bruze, Magnus ;
Cannavo, Alicia ;
Gimenez-Arnau, Ana ;
Goncalo, Margarida ;
Goossens, An ;
John, Swen M. ;
Liden, Carola ;
Lindberg, Magnus ;
Mahler, Vera ;
Matura, Mihly ;
Rustemeyer, Thomas ;
Serup, Jorgen ;
Spiewak, Radoslaw ;
Thyssen, Jacob P. ;
Vigan, Martine ;
White, Ian R. ;
Wilkinson, Mark ;
Uter, Wolfgang .
CONTACT DERMATITIS, 2015, 73 (04) :195-221
[8]   Hydrocolloid blister plaster decreases allergic contact dermatitis caused by Freestyle Libre and isobornyl acrylate [J].
Kamann, Stefanie ;
Oppel, Eva .
CONTACT DERMATITIS, 2019, 81 (05) :380-+
[9]  
Kamann Stefanie, 2018, J Diabetes Sci Technol, V12, P630, DOI 10.1177/1932296818762946
[10]  
Medicines & Healthcare products Regulatory Agency, 2019, MED DEV AL MDA 2019